CAJ | 학술논문

目的：本研究旨在观察在中国初治急性髓系白血病（AML）患者中采用标准剂量伊达比星（12 mg/m2×3 d）联合阿糖胞苷方案诱导的远近期疗效和毒副作用。方法总结了2005年5月1日至2012年4月1日在我院接受标准剂量诱导治疗的AML患者36例，按照WHO化疗方案急性及亚急性毒性分级标准进行分级和记录，分析近期疗效及远期预后。结果在36例患者中26例（72.2%）患者达到完全缓解（CR）；5例（13.9%）为部分缓解（PR），总体缓解率（ORR）为86.1%；主要3～4级毒副作用为血液学毒性（97.2%）、感染（19.5%）、胃肠道反应（8.3%）；2年总体生存率（OS）为76.4%，2年无进展生存率（PFS）为58.5%。结论在我国初治AML患者中使用标准剂量 IDA/AraC 的诱导方案能够取得较满意的近期疗效和远期预后，其毒性反应可耐受，为后续治疗创造了机会。
목적：본연구지재관찰재중국초치급성수계백혈병（AML）환자중채용표준제량이체비성（12 mg/m2×3 d）연합아당포감방안유도적원근기료효화독부작용。방법총결료2005년5월1일지2012년4월1일재아원접수표준제량유도치료적AML환자36례，안조WHO화료방안급성급아급성독성분급표준진행분급화기록，분석근기료효급원기예후。결과재36례환자중26례（72.2%）환자체도완전완해（CR）；5례（13.9%）위부분완해（PR），총체완해솔（ORR）위86.1%；주요3～4급독부작용위혈액학독성（97.2%）、감염（19.5%）、위장도반응（8.3%）；2년총체생존솔（OS）위76.4%，2년무진전생존솔（PFS）위58.5%。결론재아국초치AML환자중사용표준제량 IDA/AraC 적유도방안능구취득교만의적근기료효화원기예후，기독성반응가내수，위후속치료창조료궤회。
Objective To evaluate the treatment effects and adverse effects of standard dose idarubicin combined with cytarabine induction regimen in Chinese newly-diagnostic acute myeloid leukemia(AML) patients. Methods We retrospectively analyzed 36 AML patients treated in our center between August 1st 2005 to December 31st 2010, who received at least one cycle of standard dose idarubicin induction regimen. The acute and sub-acute adverse effects were recorded according WHO criteria. Response rate and long-term outcome were calculated. Results Among the 36 evaluable patients 26(72.2%) achieved a complete response(CR), while another 5 patients(13.9%) a partial response(PR). The overall response rate was 86.1%. Major Grade 3-4 adverse effects(AE) were hematological AEs(97.2%), infections(19.5%) and gastrointestinal AEs(8.3%). 2 years overall survival rate was 76.4%, and 2 years progression-free survival rate was 58.5%. Conclusion Standard dose IA regimen as induction for newly-diagnostic Chinese AML patients was effective and well-tolerated.